Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: Stop the merry-go-round, it's time to get off!

Antiviral Therapy

Volumn 9, Issue 2, 2004, Pages 145-148

  Angus, Peter ^a   Locarnini, Stephen ^b  

^a AUSTIN HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID MOTIFS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 2342437634     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (40)

1. Torresi J & Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118:S83-103.
2. Leung N. Clinical experience with lamivudine. Seminars in Liver Disease 2002; 22(Suppl. 1):15-21.
3. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180.
4. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
5. Delaney IV WE, Locarnini S & Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chemistry & Chemotherapy 2001; 12:1-35.
6. Delaney IV WE, Bartholomeusz A & Locarnini S. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opinion on Investigational Drugs 2002; 11(2):169-187.
7. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD & Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
8. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V & Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219-226.
9. Melegari M, Scaglioni P & Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
10. Bartholomeusz A & Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 2001; 34:432-435.
11. Liaw YF, Chien RN, Yeh CT, Tsai SL & Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
12. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Seminars in Liver Disease 2003; 23:69-79.
13. Liaw YF, Chien RN & Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antiviral Therapy 2004; 9:257-262.
14. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL & Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90.
15. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df D, Sullivan M, Kleber K, Ebrahimi R, Xiong S & Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
16. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ & Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Journal of Clinical Investigation 2001; 107:449-455.
17. Ayres A, Bartholomeusz A, Lau GK, Lam KC, Lee JY & Locarnini S. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. Journal of Clinical Virology 2003; 27:111-116.
18. Bock C, Tillmann H, Torresi J, Klempnauer J, Locarnini S, Manns M & Trautwein C. HBV polymerase mutants with enhanced replication selected during lamivudine therapy result in sudden onset of liver failure. Gastroenterology 2002; 122:264-273.
19. De Man RA, Bartholomeusz A, Niesters HGM, Zondervan PE & Locamini S. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B virus: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. Journal of Hepatology 1998; 29:669-675.
20. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T & Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. Journal of Medical Virology 1999; 59:270-276.
21. Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, Hamasaki K, Nakao K, Nakata K & Eguchi K. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94:2663-2668.
22. Feld J, Lee JY & Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003; 38:545-553.
23. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32:866-867.
24. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine 2003; 348:808-816.
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim G, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine 2003; 348:800-807.
26. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P & Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrobial Agents & Chemotherapy 2001; 45:2495-2501.
27. Shaw T, Bowden S & Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology 2004; 126:343-347.
28. Westland CE, Yang H, Delaney WE, Gibbs CS, Miller MD: Wulfsohn M, Fry J, Brosgart CL & Xiong S. Week 48 resistance surveillance in two Phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38:96-103.
29. Angus P, Vaughan R, Xiong S, Yang H, Delaney IV WE, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A & Locarnini S. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
30. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S & Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrobial Agents & Chemotherapy 2002; 46:2525-2532.
31. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N & Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis. B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123:1831-1838.
32. Westland C, Villeneuve JP, Terrault N, Zoulim F, Brosgart C, Wulfsohn M, Miller M & Xiong S. Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipixovil treatment. Hepatology 2003; 38:160A.
33. Colledge D, Civitico G, Locarnini S & Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrobial Agents & Chemotherapy 2000; 44:551-560.
34. Wang JH, Lu SN, Lee CM, Lee JF & Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scandinavian Journal of Gastroenterology 2002; 37:366-369.
35. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG & Kim CY. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clinical Infectious Disease 2001; 33:403-405.
36. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P & Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-134.
37. Locarnini S & Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV infected patients. Journal of Hepatology 1999; 30:536-550.
38. Shaw T, Bowden S. & Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002; 123:2135-2140.
39. Liaw Y, Sung J, Chow W, Shue K, Keene O & Farrell G. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003; 38:262A.
40. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, Boxall L, O'Donnell K, Shaw J, Hubscher S & Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107-113.